PMVP Stock Forecast: PMV Pharmaceuticals, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for PMV Pharmaceuticals, Inc. is $4. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 59 of 100 as at 18 Nov 2026 — in the upper half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores PMV Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (86): Reported profit is backed by cash, and the company is not expanding recklessly.
Value (23): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
PMVP stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on PMVP, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 4 Sept 2026 | HC Wainwright & Co. | Reiterates | Buy | $5.00 |
| 8 July 2026 | Ladenburg Thalmann | Assumes | Buy | $3.00 |
| 13 May 2026 | Oppenheimer | Maintains | Outperform | — |
| 20 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 20 Aug 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 30 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 14 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 13 May 2024 | Craig-Hallum | Initiates | Buy | — |
| 12 Apr 2024 | Jefferies | Initiates | Buy | — |
| 7 Mar 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 27 Dec 2023 | Ladenburg Thalmann | Initiates | Buy | — |
| 16 Oct 2023 | HC Wainwright & Co. | Maintains | Buy | — |
| 11 Aug 2023 | HC Wainwright & Co. | Maintains | Buy | — |
| 17 May 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 11 May 2023 | Oppenheimer | Reiterates | Outperform | — |
| 20 Mar 2023 | HC Wainwright & Co. | Maintains | Buy | — |
| 2 Mar 2023 | Oppenheimer | Maintains | Outperform | — |
| 17 Nov 2022 | HC Wainwright & Co. | Maintains | Buy | — |
| 9 June 2022 | Oppenheimer | Maintains | Outperform | — |
| 24 May 2022 | Goldman Sachs | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for PMVP.
This page is one stock. Monday covers all of them.
PMVP appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
PMVP vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 19 Nov 2026, PMV Pharmaceuticals, Inc. returned −3.7% against +9.2% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
PMVP analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- 1.7×
- EV / EBITDA
- —
Cheaper than 51% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −99.4%
- Return on assets
- −39.3%
- Dividend yield
- —
Higher than 13% of US stocks
Higher than 11% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
PMV Pharmaceuticals, Inc. has a market value of $92.2M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$75.2M.
Free cash flow in the twelve months to 30 June 2026: −$71.3M.
PMV Pharmaceuticals, Inc. employs 54 people.
Data provided by Twelve Data
PMVP and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at PMVP’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own PMV Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about PMVP
What is the PMVP stock price forecast for 2026-2027?
The median 12-month analyst price target for PMV Pharmaceuticals, Inc. is $4, with estimates ranging from $3 to $5. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is PMVP stock a buy right now?
Of the 5 analysts covering PMV Pharmaceuticals, Inc., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks PMV Pharmaceuticals, Inc. 59 out of 100 across roughly 4,300 US stocks as at 18 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank PMVP?
As at 18 Nov 2026, PMV Pharmaceuticals, Inc. ranks 59 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (86 of 100).
Will PMVP stock go up?
No one can know that. What the data says: the median 12-month target from 5 analysts is $4, and Ticker Nerd's factor model ranks PMV Pharmaceuticals, Inc. 59 out of 100 as at 18 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the PMVP stock forecast for 2030?
No analyst covering PMV Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PMVP are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3 to $5 over the next 12 months.
How has PMVP stock performed over the past year?
PMV Pharmaceuticals, Inc. returned -3.7% over the 12 months to 19 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does PMV Pharmaceuticals, Inc. do?
PMV Pharmaceuticals, Inc. is a precision oncology biotechnology company focused on discovering and developing small-molecule therapies that target p53 mutations in cancer. The company’s lead program, rezatapopt, is designed as a selective p53 reactivator for tumors carrying the Y220C mutation, with a tumor-agnostic approach that aims to address cancers across multiple tissue types.
About PMV Pharmaceuticals, Inc.
PMV Pharmaceuticals, Inc. is a precision oncology biotechnology company focused on discovering and developing small-molecule therapies that target p53 mutations in cancer. The company’s lead program, rezatapopt, is designed as a selective p53 reactivator for tumors carrying the Y220C mutation, with a tumor-agnostic approach that aims to address cancers across multiple tissue types. PMV Pharmaceuticals concentrates on translational research and clinical development for advanced solid tumors, combining drug discovery with mutation-specific biology to create targeted treatment options. Based in Princeton, New Jersey, the company operates within the broader cancer therapeutics market and is recognized for its work in mutant p53 biology and small-molecule precision medicine.
CEO Dr. David H. Mack Ph.D. · 54 employees · United States · https://www.pmvpharma.com